Pearl Technology: Curative Hyaline Cartilage Restoration.
The first tissue engineering platform designed to deliver native, mechanically robust hyaline cartilage, enabling structural and functional restoration in patients with cartilage damage from injury or osteoarthritis.
Mechanism of Action: Preserving Native Properties.
ArThec’s core innovation is preserving the intrinsic properties of the cartilage tissue throughout the production process, resulting in the delivery of already-formed cartilage. This proprietary approach bypasses the critical failure of conventional cell suspension techniques, which often lead to chondrocytes losing their proper phenotype and forming fibrous tissue instead of stable hyaline cartilage.
Design-driven clinical effect.
The final implant possesses full histological, biochemical, and mechanical properties of native cartilage tissue. This engineered construct ensures stability, elasticity, and high resistance to friction and compression. Critically, this identity stimulates natural integration with the surrounding native cartilage tissue, with the mechanism involving the migration of chondrocytes into the extracellular matrix. The product is compsed of autologous material (the patient’s own tissue), guaranteeing close to zero risk of rejection or high immunogeneicity.
Proprietary Devices for Optimized Harvesting.
The procedure utilizes ArThec’s innovative proprietary devices. The Proprietary Trocar (puncture biopsy tool) is designed to minimize the invasiveness of the initial harvesting stage. It targets a nonloaded area of the joint and isolates only a very small tissue sample. This minimal volume creates ideal conditions for the self-healing of the extraction site, thereby avoiding donor site morbidity associated with larger biopsies. The tissue is harvested in an ideal shape to maximize efficiency. The innovative system uses GMP-compliant hardware optimized to precisely process the tissue during manufacturing, ensuring ideal reproducibility and minimal tissue loss.
Scalability and Ease of Use.
The process is designed for robust commercial viability, facilitating technology transfer to appropriately certified manufacturing facilities, and can be reliably executed by trained professional personnel.
What do professionals think?
The final product possesses full histological, biochemical, and mechanical properties of native cartilage tissue, ensuring stability, elasticity, resistance to friction/compression, and natural integration with surrounding tissue.
The procedure can be reliably performed by appropriately trained personnel and is not limited by location, allowing it to be conducted in any suitably certified facility.
Comparative Analysis: Advantages in Outcome and Procedure.
Demonstrating Pearl’s definitive advantages over traditional cell-based therapies and osteochondral transfer techniques.
Addressing the Unmet Medical Need.
Osteoarthritis (OA) is characterized by the progressive and irreversible loss of joint cartilage. PEARL is positioned as the first technology designed to address one of the major contributors to OA—cartilage damage from injury or degeneration—aiming to prevent severe consequences such as joint replacement. Its key value proposition is reducing or eliminating the need for joint removal and artificial endoprosthesis implantation.
Superiority Over Cell Suspensions and Scaffolds.
Many existing biological approaches provide only temporary clinical benefits, often producing fibrous tissue instead of stable hyaline cartilage. Pearl, however, restores full-sized, mechanically robust cartilage that fills entire defects and re-establishes the natural joint surface, achieving results beyond the reach of current methods.
Risks Associated with Foreign Material.
Pearl exclusively uses autologous material, eliminating the risks associated with foreign or animal-derived components. Therapies relying on non-autologous materials have historically faced challenges due to immunogenicity and the potential for adverse reactions, including inflammation and graft failure.
Overcoming the Limitations of Traditional Osteochondral Grafting.
Pearl addresses the major clinical limitations associated with traditional osteochondral grafting procedures. It requires a relatively small tissue sample—smaller than what is needed for conventional grafting—which heals naturally and reduces donor site complications. The procedure is significantly easier to perform than traditional methods, and the resulting cartilage is homogeneous, precisely matching the natural curvature of the joint and avoiding uneven surface properties.
Procedural and Recovery Benefits.
Pearl is minimally invasive and does not require mechanical fasteners or extensive stitching, protecting surrounding tissues. The implanted cartilage is elastic, mechanically resilient, and fully compatible with native tissue, allowing normal joint movement to stimulate cell activity. This can accelerate rehabilitation and support a faster return to full joint function.
What do professionals think?
The final product possesses full histological, biochemical, and mechanical properties of native cartilage tissue, ensuring stability, elasticity, resistance to friction/compression, and natural integration with surrounding tissue.
The procedure can be reliably performed by appropriately trained personnel and is not limited by location, allowing it to be conducted in any suitably certified facility.
Regulatory Pathway and Clinical Development.
Confirmed ATMP status, planned multiple designations, and an existing clinical data.
Regulatory Classification and Status.
In Europe, the PEARL product has been officially classified by EMA/CAT as a tissue-engineered Advanced Therapy Medicinal Product (ATMP), a status granted in May 2021. In the USA, the product is classified as a Cell and Gene Therapy Product and is regulated by the FDA under the Biologics License Application (BLA) pathway.
Strategy for Development and Regulatory Engagement.
PEARL is being developed to address a critical medical need in patients with osteoarthritis, particularly in populations for whom current therapeutic options do not adequately support long-term preservation of joint structure and function. In this context, advanced therapy medicinal products represent an increasingly important therapeutic class with the potential to address disease mechanisms beyond symptomatic management. Recognising both the complexity and the innovative nature of ATMP development, ArThec intends to pursue early and constructive dialogue with regulatory authorities to seek scientific and regulatory guidance throughout the development process. This approach is aimed at supporting a well-designed and efficient development programme, optimising regulatory interactions, and ensuring that PEARL is advanced in full alignment with established standards for safety, quality, and efficacy.
Market and Health Economics.
The market opportunity is substantial, addressing a global patient population with early to moderate OA (Kellgren and Lawrence I–III), estimated at 177 million globally in 2024.
PEARL represents a highly attractive alternative to endoprosthetics for healthcare payers due to the high social and economic cost associated with joint replacement. Endoprostheses require costly revision surgeries (1–3 per patient in younger groups) and long-term care, which PEARL aims to eliminate. Revision surgery costs are significantly higher than primary replacement, carrying a high financial burden and increased risk of permanent disability.
Clinical development of PEARL.
The current clinical development status of PEARL at ArThec is that, since mid-2025, we have been conducting a First-in-Human study. This study is being carried out under Hospital Exemption regulations. We are extremely pleased to observe that both the safety and efficacy profiles are very favorable. Our patients have successfully undergone the primary treatment, are rehabilitating quickly, and remain under our long-term monitoring and care. The results have been remarkable. We are delighted that we were able to help patients even before official regulatory approval. We are planning subsequent studies involving a larger patient population to support future registration purposes.
What do professionals think?
The final product possesses full histological, biochemical, and mechanical properties of native cartilage tissue, ensuring stability, elasticity, resistance to friction/compression, and natural integration with surrounding tissue.
The procedure can be reliably performed by appropriately trained personnel and is not limited by location, allowing it to be conducted in any suitably certified facility.
